CAPTRUST Financial Advisors
BLCM

CAPTRUST Financial Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

CAPTRUST Financial Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-30
Closed – – 4452
2022
Q2 		$0 Buy
+30
New +$45 ﹤0.01% 5238
2022
Q1 		– Sell
-30
Closed – – 5239
2021
Q4 		$0 Hold
30
– – ﹤0.01% 5004
2021
Q3 		$0 Hold
30
– – ﹤0.01% 4831
2021
Q2 		$0 Hold
30
– – ﹤0.01% 4721
2021
Q1 		$0 Hold
30
– – ﹤0.01% 4523
2020
Q4 		$0 Buy
30
+4
+15% +$17 ﹤0.01% 3560
2020
Q3 		$0 Sell
26
-30
-54% -$203 ﹤0.01% 3305
2020
Q2 		$0 Buy
+56
New +$381 ﹤0.01% 2924
2019
Q4 		– Sell
-27
Closed – – 1924
2019
Q3 		$0 Sell
27
-15
-36% -$196 ﹤0.01% 2045
2019
Q2 		$1K Hold
42
– – ﹤0.01% 1890
2019
Q1 		$1K Sell
42
-26
-38% -$869 ﹤0.01% 1777
2018
Q4 		$2K Hold
68
– – ﹤0.01% 1509
2018
Q3 		$4K Hold
68
– – ﹤0.01% 1415
2018
Q2 		$5K Buy
+68
New +$5.3K ﹤0.01% 1333

Other funds holding BLCM

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAPTRUST Financial Advisors's BLCM Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2022, closing a stake of 30 shares.

CAPTRUST Financial Advisors first reported a position in BLCM in Q2 2018 and held it in 14 quarters. The position peaked at $5K in Q2 2018. 28 funds tracked by Wall St. Rank hold BLCM as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 30 Bellicum Pharmaceuticals, Inc. shares in Q3 2022.
  • CAPTRUST Financial Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2018 and held it in 14 quarters.
  • CAPTRUST Financial Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $5K in Q2 2018.
  • 28 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.